VolitionRx Q1 revenue $0.25M (+44% YoY); first commercial revenue from CE-marked Nu.Q NETs in Europe

VOLITIONRX LTD

2025-Q1 EPS reported -$0.06 revenue$246,385

Revenue of ~$0.25M in Q1 2025, up 44% from Q1 2024; first revenue from regulated CE-marked Nu.Q NETs automated product.
Net cash used in ops averaged $1.4M/month, down ~50% vs Q1 2024; cash balance $2.6M at March 31, 2025.
Post-quarter closed $6.25M convertible loan note (24-month, 6-month repayment holiday).
Confidential licensing discussions with >10 companies; combined market cap of seven >$600B.
Goal to be cash neutral on full-year 2025 basis via licensing receipts and cost reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.